Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

NCT ID: NCT00765882

Last Updated: 2013-01-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

633 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2009-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Linaclotide 290 micrograms

Group Type EXPERIMENTAL

Linaclotide 290 micrograms

Intervention Type DRUG

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

2

Linaclotide 145 micrograms

Group Type EXPERIMENTAL

Linaclotide 145 micrograms

Intervention Type DRUG

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

3

Matching placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Linaclotide 290 micrograms

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

Intervention Type DRUG

Linaclotide 145 micrograms

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

Intervention Type DRUG

Placebo

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings
* Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests
* Patient meets protocol criteria for CC: reports \< 3 bowel movements per week and reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation during \> 25% of BMs
* Patient demonstrates continued chronic constipation through Pretreatment Period
* Patient is compliant with IVRS

Exclusion Criteria

* Patient has history of loose or watery stools
* Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)
* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility
* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ironwood Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role collaborator

Forest Laboratories

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul F.C. Eng, PhD

Role: STUDY_DIRECTOR

Forest Laboratories

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Forest Investigative Site

Birmingham, Alabama, United States

Site Status

Forest Investigative Site

Birmingham, Alabama, United States

Site Status

Forest Investigative Site

Huntsville, Alabama, United States

Site Status

Forest Investigative Site

Chandler, Arizona, United States

Site Status

Forest Investigative Site

Mesa, Arizona, United States

Site Status

Forest Investigative Site

Peoria, Arizona, United States

Site Status

Forest Investigative Site

Phoenix, Arizona, United States

Site Status

Forest Investigative Site

Scottsdale, Arizona, United States

Site Status

Forest Investigative Site

Tucson, Arizona, United States

Site Status

Forest Investigative Site

Burbank, California, United States

Site Status

Forest Investigative Site

Encinitas, California, United States

Site Status

Forest Investigative Site

Foothill Ranch, California, United States

Site Status

Forest Investigative Site

Los Angeles, California, United States

Site Status

Forest Investigative Site

Orange, California, United States

Site Status

Forest Investigative Site

Westlake Village, California, United States

Site Status

Forest Investigative Site

Boulder, Colorado, United States

Site Status

Forest Investigative Site

Colorado Springs, Colorado, United States

Site Status

Forest Investigative Sites

Denver, Colorado, United States

Site Status

Forest Investigative Site

Longmont, Colorado, United States

Site Status

Forest Investigative Site

Wheat Ridge, Colorado, United States

Site Status

Forest Investigative Site

Waterbury, Connecticut, United States

Site Status

Forest Investigative Site

Boca Raton, Florida, United States

Site Status

Forest Investigative Site

Bradenton, Florida, United States

Site Status

Forest Investigative Site

Brooksville, Florida, United States

Site Status

Forest Investigative Site

Fort Myers, Florida, United States

Site Status

Forest Investigative Site

Jupiter, Florida, United States

Site Status

Forest Investigative Site

Kissimmee, Florida, United States

Site Status

Forest Investigative Site

Miami, Florida, United States

Site Status

Forest Investigative Site

Ocala, Florida, United States

Site Status

Forest Investigative Site

Orlando, Florida, United States

Site Status

Forest Investigative Site

Panama City, Florida, United States

Site Status

Forest Investigative Site

Pembroke Pines, Florida, United States

Site Status

Forest Investigative Site

St. Petersburg, Florida, United States

Site Status

Forest Investigative Site

Tampa, Florida, United States

Site Status

Forest Investigative Site

Trinity, Florida, United States

Site Status

Forest Investigative Site

Zephyrhills, Florida, United States

Site Status

Forest Investigative Site

Atlanta, Georgia, United States

Site Status

Forest Investigative Site

Marietta, Georgia, United States

Site Status

Forest Investigative Site

Marietta, Georgia, United States

Site Status

Forest Investigative Site

Stockbridge, Georgia, United States

Site Status

Forest Investigative Site

Woodstock, Georgia, United States

Site Status

Forest Investigative Site

Idaho Falls, Idaho, United States

Site Status

Forest Investigative Site

Rockford, Illinois, United States

Site Status

Forest Investigative Site

Elkhart, Indiana, United States

Site Status

Forest Investigative Site

Evansville, Indiana, United States

Site Status

Forest Investigative Site

Indianapolis, Indiana, United States

Site Status

Forest Investigative Site

Indianapolis, Indiana, United States

Site Status

Forest Investigative Site

Iowa City, Iowa, United States

Site Status

Forest Investigative Site

Arkansas City, Kansas, United States

Site Status

Forest Investigative Site

Newton, Kansas, United States

Site Status

Forest Investigative Site

Wichita, Kansas, United States

Site Status

Forest Investigative Site

Wichita, Kansas, United States

Site Status

Forest Investigative Site

Lexington, Kentucky, United States

Site Status

Forest Investigative Site

Madisonville, Kentucky, United States

Site Status

Forest Investigative Site

Chevy Chase, Maryland, United States

Site Status

Forest Investigative Site

Hagerstown, Maryland, United States

Site Status

Forest Investigative Site

Lutherville, Maryland, United States

Site Status

Forest Investigative Site

Boston, Massachusetts, United States

Site Status

Forest Investigative Site

Chaska, Minnesota, United States

Site Status

Forest Investigative Site

St Louis, Missouri, United States

Site Status

Forest Investigative Site

St Louis, Missouri, United States

Site Status

Forest Investigative Site

Vineland, New Jersey, United States

Site Status

Forest Investigative Site

Albuquerque, New Mexico, United States

Site Status

Forest Investigative Site

Brooklyn, New York, United States

Site Status

Forest Investigative Site

Great Neck, New York, United States

Site Status

Forest Investigative Site

Great Neck, New York, United States

Site Status

Forest Investigative Site

Fayetteville, North Carolina, United States

Site Status

Forest Investigative Site

Greensboro, North Carolina, United States

Site Status

Forest Investigative Site

Hickory, North Carolina, United States

Site Status

Forest Investigative Site

Raleigh, North Carolina, United States

Site Status

Forest Investigative Site

Wilmington, North Carolina, United States

Site Status

Forest Investigative Site

Winston-Salem, North Carolina, United States

Site Status

Forest Investigative Site

Bismarck, North Dakota, United States

Site Status

Forest Investigative Site

Akron, Ohio, United States

Site Status

Forest Investigative Site

Cincinnati, Ohio, United States

Site Status

Forest Investigative Site

Cleveland, Ohio, United States

Site Status

Forest Investigative Site

Oklahoma City, Oklahoma, United States

Site Status

Forest Investigative Site

Tulsa, Oklahoma, United States

Site Status

Forest Investigative Site

Bensalem, Pennsylvania, United States

Site Status

Forest Investigative Site

Pittsburgh, Pennsylvania, United States

Site Status

Forest Investigative Site

Greenville, South Carolina, United States

Site Status

Forest Investigative Site

Greer, South Carolina, United States

Site Status

Forest Investigative Site

Nashville, Tennessee, United States

Site Status

Forest Investigative Site

Austin, Texas, United States

Site Status

Forest Investigative Site

Dallas, Texas, United States

Site Status

Forest Investigative Site

Houston, Texas, United States

Site Status

Forest Investigative Site

Lake Jackson, Texas, United States

Site Status

Forest Investigative Site

San Antonio, Texas, United States

Site Status

Forest Investigative Site

San Antonio, Texas, United States

Site Status

Forest Investigative Site

Salt Lake City, Utah, United States

Site Status

Forest Investigative Site

Charlottesville, Virginia, United States

Site Status

Forest Investigative Site

Christianburg, Virginia, United States

Site Status

Forest Investigative Site

Newport News, Virginia, United States

Site Status

Forest Investigative Site

Norfolk, Virginia, United States

Site Status

Forest Investigative Site

Norfolk, Virginia, United States

Site Status

Forest Investigative Site

Richmond, Virginia, United States

Site Status

Forest Investigative Site

Bellevue, Washington, United States

Site Status

Forest Investigative Site

Lakewood, Washington, United States

Site Status

Forest Investigative Site

Wenatchee, Washington, United States

Site Status

Forest Investigative Site

Milwaukee, Wisconsin, United States

Site Status

Forest Investigative Site

Vancouver, British Columbia, Canada

Site Status

Forest Investigative Site

Greater Sudbury, Ontario, Canada

Site Status

Forest Investigative Site

Hamilton, Ontario, Canada

Site Status

Forest Investigative Site

Newmarket, Ontario, Canada

Site Status

Forest Investigative Site

Ottawa, Ontario, Canada

Site Status

Forest Investigative Site 1

Sarnia, Ontario, Canada

Site Status

Forest Investigative Site 2

Sarnia, Ontario, Canada

Site Status

Forest Investigative Site

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Chang L, Lembo AJ, Lavins BJ, Shiff SJ, Hao X, Chickering JG, Jia XD, Currie MG, Kurtz CB, Johnston JM. The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. Aliment Pharmacol Ther. 2014 Dec;40(11-12):1302-12. doi: 10.1111/apt.12985. Epub 2014 Oct 13.

Reference Type DERIVED
PMID: 25312449 (View on PubMed)

Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, Shao JZ, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Eng P, Fox SM, Johnston JM. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011 Aug 11;365(6):527-36. doi: 10.1056/NEJMoa1010863.

Reference Type DERIVED
PMID: 21830967 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LIN-MD-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect to Linaclotide on Colonic Motility
NCT06989268 COMPLETED PHASE4
Linaclotide for Colonoscopy Bowel Prep
NCT06692673 RECRUITING PHASE1/PHASE2